title: Apatinib for the treatment of gastric cancer.
abstract: BACKGROUND
  Apatinib, a small-molecule inhibitor of vascular endothelial growth factor receptor 2, has demonstrated encouraging anti-cancer activity in gastric cancer within both in vitro and in vivo models.
  
  
  METHODS
  Apatinib's efficacy, tolerability and safety have been evaluated in one Phase II and one Phase III study in metastatic/advanced gastric cancer. In this review, we focus on the mechanism of action of apatinib, its pharmacokinetic profile and its clinical activity in the treatment of advanced/metastatic gastric cancer. Expert commentary: Unfortunately, as yet, there is no definitive biomarker data for apatinib in gastric cancer.
authors.affiliation: a Department of Molecular and Translational Medicine , University of Brescia , Brescia , Italy.|b Unit of Molecular Therapy and Pharmacogenomic , ASST Cremona , Cremona , Italy.
authors.forename: Giandomenico
authors.initials: G
authors.lastname: Roviello
authors.affiliation: c Section of Experimental Oncology, Department of Clinical and Experimental Medicine , University of Parma , Parma , Italy.
authors.forename: Andrea
authors.initials: A
authors.lastname: Ravelli
authors.affiliation: d Pharmacology Unit , University of Siena , Siena , Italy.
authors.forename: Anna Ida
authors.initials: AI
authors.lastname: Fiaschi
authors.affiliation: b Unit of Molecular Therapy and Pharmacogenomic , ASST Cremona , Cremona , Italy.
authors.forename: Maria Rosa
authors.initials: MR
authors.lastname: Cappelletti
authors.affiliation: b Unit of Molecular Therapy and Pharmacogenomic , ASST Cremona , Cremona , Italy.
authors.forename: Angela
authors.initials: A
authors.lastname: Gobbi
authors.affiliation: b Unit of Molecular Therapy and Pharmacogenomic , ASST Cremona , Cremona , Italy.
authors.forename: Chiara
authors.initials: C
authors.lastname: Senti
authors.affiliation: b Unit of Molecular Therapy and Pharmacogenomic , ASST Cremona , Cremona , Italy.
authors.forename: Laura
authors.initials: L
authors.lastname: Zanotti
authors.affiliation: e Department of Medical, Surgical and Neuroscience; Unit of General and Minimally Invasive Surgery , University of Siena , Siena , Italy.
authors.forename: Karol
authors.initials: K
authors.lastname: Polom
authors.affiliation: f Tumour Biology Team, Breast Cancer Now Research Centre , The Institute of Cancer Research , London , UK.
authors.forename: Andrew R
authors.initials: AR
authors.lastname: Reynolds
authors.affiliation: g Department of Pathology, Peter Mac Callum Cancer Centre, Department of Pathology , University of Melbourne , Melbourne , Australia.
authors.forename: Stephen B
authors.initials: SB
authors.lastname: Fox
authors.affiliation: b Unit of Molecular Therapy and Pharmacogenomic , ASST Cremona , Cremona , Italy.|h Department of Medical, Surgery and Health Sciences , University of Trieste , Trieste , Italy.
authors.forename: Daniele
authors.initials: D
authors.lastname: Generali
mesh_terms: D020533:Angiogenesis Inhibitors / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D000818:Animals; D006801:Humans; D058990:Molecular Targeted Therapy; D009389:Neovascularization, Pathologic; D047428:Protein Kinase Inhibitors / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D011725:Pyridines / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D015398:Signal Transduction / Q000187:drug effects; D013274:Stomach Neoplasms / Q000098:blood supply / Q000188:drug therapy* / Q000201:enzymology / Q000473:pathology; D016896:Treatment Outcome; D040301:Vascular Endothelial Growth Factor Receptor-2 / Q000037:antagonists & inhibitors* / Q000378:metabolism
chemical_list: D020533:Angiogenesis Inhibitors; D047428:Protein Kinase Inhibitors; D011725:Pyridines; C553458:apatinib; C000588866:KDR protein, human; D040301:Vascular Endothelial Growth Factor Receptor-2
keywords: Gastric cancer; VEGFR2; angiogenesis; apatinib; chemotherapy